Departments of Drug Discovery and Biomedical Sciences and Public Health, Colleges of Pharmacy and Medicine, Medical University of South Carolina, Charleston, South Carolina 29425, United States.
Department of Chemistry, University of Malaya, Kuala Lumpur 50603, Malaysia.
J Nat Prod. 2021 Nov 26;84(11):3001-3007. doi: 10.1021/acs.jnatprod.1c00625. Epub 2021 Oct 22.
The pressing need for SARS-CoV-2 controls has led to a reassessment of strategies to identify and develop natural product inhibitors of zoonotic, highly virulent, and rapidly emerging viruses. This review article addresses how contemporary approaches involving computational chemistry, natural product (NP) and protein databases, and mass spectrometry (MS) derived target-ligand interaction analysis can be utilized to expedite the interrogation of NP structures while minimizing the time and expense of extraction, purification, and screening in BioSafety Laboratories (BSL)3 laboratories. The unparalleled structural diversity and complexity of NPs is an extraordinary resource for the discovery and development of broad-spectrum inhibitors of viral genera, including , which contains MERS, SARS, SARS-CoV-2, and the common cold. There are two key technological advances that have created unique opportunities for the identification of NP prototypes with greater efficiency: (1) the application of structural databases for NPs and target proteins and (2) the application of modern MS techniques to assess protein-ligand interactions directly from NP extracts. These approaches, developed over years, now allow for the identification and isolation of unique antiviral ligands without the immediate need for BSL3 facilities. Overall, the goal is to improve the success rate of NP-based screening by focusing resources on source materials with a higher likelihood of success, while simultaneously providing opportunities for the discovery of novel ligands to selectively target proteins involved in viral infection.
迫切需要控制 SARS-CoV-2,这促使人们重新评估识别和开发针对人畜共患、高毒力和快速出现的病毒的天然产物抑制剂的策略。本文探讨了如何利用涉及计算化学、天然产物 (NP) 和蛋白质数据库以及质谱 (MS) 衍生的靶标-配体相互作用分析的现代方法,加快 NP 结构的研究,同时最大程度地减少在生物安全实验室 (BSL)3 实验室中提取、纯化和筛选的时间和费用。NP 无与伦比的结构多样性和复杂性是发现和开发广谱病毒属抑制剂的宝贵资源,包括 MERS、SARS、SARS-CoV-2 和普通感冒。有两个关键的技术进步为提高识别 NP 原型的效率创造了独特的机会:(1) NP 和靶蛋白结构数据库的应用,(2) 现代 MS 技术直接从 NP 提取物评估蛋白-配体相互作用的应用。这些方法经过多年的发展,现在允许在不需要 BSL3 设施的情况下,识别和分离具有独特抗病毒活性的配体。总的来说,目标是通过将资源集中在更有可能成功的源材料上,提高基于 NP 的筛选的成功率,同时为发现选择性针对病毒感染相关蛋白的新型配体提供机会。